Despite being preventable and curable since the middle of the twentieth century, tuberculosis (TB) has long persisted as the world's deadliest infectious disease, with the communities most devastated by TB among the poorest and most vulnerable in the world. Only about half of people with TB receive successful treatment each year. As the global threat of antimicrobial resistance continues to escalate, so do cases of drug-resistant TB, or TB that is resistant to various antibiotics that constitute standard treatment regimens. In response, the National Academies of Sciences, Engineering, and Medicine's Forum on Microbial Threats held a two-part virtual workshop on July 22 and September 14-16, 2021 titled Innovations for Tackling Tuberculosis in the Time of COVID-19. The aims of the workshop were to evaluate the current status of TB elimination, assess the effects of the COVID-19 pandemic on the global fight against TB, and examine technical and strategic innovations that could be leveraged to meet the United Nations High-Level Meeting on Tuberculosis targets in 2022 and The World Health Organization's END TB Strategy targets by 2030. This publication summarizes the presentations and discussions of the workshop.

Contents

• The National Academies of SCIENCES • ENGINEERING • MEDICINE
• COMMITTEE ON INNOVATIONS FOR TACKLING TUBERCULOSIS IN THE TIME OF COVID-19: A TWO-PART WORKSHOP
• FORUM ON MICROBIAL THREATS
• Reviewers
• Acknowledgments
• Acronyms and Abbreviations
• 1. Introduction
  • WORKSHOP OBJECTIVES
  • ORGANIZATION OF THE PROCEEDINGS OF THE WORKSHOP
• 2. Current Tools and Challenges
  • LEADERSHIP FROM PUBLIC HEALTH WORKERS IN ENDING TUBERCULOSIS—PAST AND PRESENT
    Jim Yong Kim.
  • PROGRESS TOWARD GLOBAL TUBERCULOSIS ELIMINATION GOALS AND OPPORTUNITIES FOR MOVING FORWARD
    Salmaan Keshavjee.
  • CHALLENGES AND INNOVATIONS
    Eric Rubin.
  • NEW TECHNOLOGIES AND REMAINING GAPS IN TUBERCULOSIS DIAGNOSTICS
    Soumya Swaminathan.
  • IMPROVING TREATMENT REGIMENS AND VACCINE DEVELOPMENT
    Emilio Emini.
  • COLLECTIVE SOCIAL VALUE OF INFECTIOUS DISEASE INTERVENTIONS
    Kevin Outterson.
  • DISCUSSION
• 3. Detection
  • USAID’S COMMITMENT TO ADDRESSING TUBERCULOSIS WORLDWIDE
    Jennifer Adams.
  • BUILDING A TUBERCULOSIS-FREE WORLD: PROGRESS UPDATE
    Eric Goosby.
  • REALITIES OF MULTIDRUG-RESISTANT TUBERCULOSIS
    Matteo Zignol.
  • RAPID ACCELERATION OF DIAGNOSTICS TECHNOLOGY: COVID-19 PANDEMIC EXPERIENCE
    Matthew McMahon.
  • ADVANCES IN TUBERCULOSIS DIAGNOSTICS
  • IMPROVING ADHERENCE, INFECTION CONTROL CAPACITIES, AND COST-EFFECTIVENESS
• 4. Vaccines and Therapeutics
  • EXISTING TOOLS AND NEW TECHNOLOGIES
  • TRANSFORMING TREATMENT OPTIONS
  • REFLECTIONS AND DISCUSSION ON CRITICAL ELEMENTS FOR IMPLEMENTATION
  • DISCUSSION
• 5. Financing, Ambition, and Preparedness
  • A PLACE FOR TUBERCULOSIS IN THE PANDEMIC PREPAREDNESS AGENDA
    Tharman Shanmugaratnam.
  • ACHIEVING SYNERGY IN GLOBAL HEALTH SECURITY PREPAREDNESS AGAINST RESPIRATORY PATHOGENS
  • MAKING THE CASE FOR FINANCING TUBERCULOSIS ELIMINATION
  • FINAL COMMENTS
• Appendix A. REFERENCES
• Appendix B. Workshop Statement of Task
• Appendix C. Workshop Agenda

Suggested citation:

National Academies of Sciences, Engineering, and Medicine. 2022. Innovations for tackling tuberculosis in the time of COVID-19: Proceedings of a workshop. Washington, DC: The National Academies Press. https://doi.org/10.17226/26530.

Digital Object Identifier: https://doi.org/10.17226/26530

This publication is available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.

Printed in the United States of America